imeglimin and Liver-Diseases

Imeglimin is a novel oral antidiabetic drug used to treat type 2 diabetes, targeting the mitochondrial bioenergetics. Imeglimin is mainly excreted unchanged by the kidneys and is a substrate of organic cation transporters, which are expressed in the kidney and the liver.. The aim of this study was to assess the effect of hepatic impairment on the pharmacokinetics of imeglimin.. An open-label, single-dose, parallel-group study was carried out in seven subjects with normal hepatic function and seven subjects with moderate hepatic impairment who received a single dose of imeglimin 1000 mg. Blood and urine samples were collected up to 48 h after imeglimin administration. Pharmacokinetics were determined using non-compartmental methods.. Imeglimin was safe and well tolerated in all subjects.. EudraCT 2018-001950-83.

Topics: Area Under Curve; Diabetes Mellitus, Type 2; Humans; Liver Diseases; Triazines